Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04552743 | MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma | completed | Phase 2 | 25 | Surbhi Sidana, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT00599495 | Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT | completed | Phase 2 | 50 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Sep 2, 2022 |
| clinicaltrials |
| NCT00784823 | Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma(Mel-Vel) | completed | Phase 1 / Phase 2 | 32 | Hackensack Meridian HealthOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT01119066 | HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | completed | Phase 2 | 422 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT02384083 | Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients | completed | Phase 1 / Phase 2 | 47 | PETHEMA FoundationOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT02272803 | Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan | completed | Phase 2 | 82 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT02977494 | Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment(GMMG-DANTE) | completed | Phase 2 | 22 | Universitätsklinikum Hamburg-EppendorfOTHER | 2 | May 31, 2022 | clinicaltrials |
| NCT01849783 | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | completed | Phase 2 | 41 | Margarida Magalhaes-SilvermanOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT01463670 | Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance | completed | Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT01658241 | Panobinostat Biological Correlates Study(VEG VCA1) | completed | Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03964688 | Effect of Vitamin C in Autologous Stem Cell Transplantations(VICAST) | completed | Phase 2 | 47 | Maastricht University Medical CenterOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT01989598 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03697629 | A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 40 | Canadian Myeloma Research GroupOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT01496118 | Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 80 | SCRI Development Innovations, LLCOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT02424851 | Optimising Renal Outcome in Myeloma Renal Failure(OPTIMAL) | completed | Phase 2 | 31 | Oxford University Hospitals NHS TrustOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT04065789 | Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients(KyDaR) | completed | Phase 2 | 41 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jan 27, 2022 | clinicaltrials |
| NCT01962792 | Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 84 | Pharmacyclics LLC.INDUSTRY | 2 | Dec 21, 2021 | clinicaltrials |
| NCT02086552 | Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT01131169 | Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions | completed | Phase 2 | 66 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT01793051 | Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma | completed | Phase 2 | 88 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT01421186 | A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 91 | MorphoSys AGINDUSTRY | 2 | Nov 16, 2021 | clinicaltrials |
| NCT00177047 | Autologous Transplant for Multiple Myeloma | completed | Phase 2 / Phase 3 | 363 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT01054144 | Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 13, 2021 | clinicaltrials |
| NCT02951819 | A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma | completed | Phase 2 | 101 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT02169791 | Nonmyeloablative Haploidentical Transplant Followed by MLN9708 | completed | Phase 2 | 29 | Northside Hospital, Inc.OTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT02045017 | Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency | completed | Phase 2 | 81 | CelgeneINDUSTRY | 8 | Aug 27, 2021 | clinicaltrials |
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Molecular Partners AGINDUSTRY | 6 | Aug 25, 2021 | clinicaltrials |
| NCT00421525 | Phase I/II Study of hLL1 in Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01720875 | Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)(MUKfour) | completed | Phase 2 | 16 | University of LeedsOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | completed | Phase 1 / Phase 2 | 38 | AbbVieINDUSTRY | 1 | Aug 2, 2021 | clinicaltrials |
| NCT03665155 | First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody | completed | Phase 1 / Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT04439240 | Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2021 | clinicaltrials |
| NCT02703779 | Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) | completed | Phase 2 | 101 | Siddhartha GangulyOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT02499081 | UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment | completed | Phase 2 | 20 | University of ArkansasOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT02420223 | Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients | completed | Phase 2 | 25 | Medical College of WisconsinOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT00151203 | Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma | completed | Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | May 27, 2021 | clinicaltrials |
| NCT00538733 | Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma(T-BiRD) | completed | Phase 2 | 26 | Weill Medical College of Cornell UniversityOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT01018979 | Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | completed | Phase 2 | 19 | GPCR Therapeutics, Inc.INDUSTRY | 1 | May 11, 2021 | clinicaltrials |
| NCT01177735 | Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma | completed | Phase 2 | 71 | University of ArkansasOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT01458288 | A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease | completed | Phase 2 | 12 | GPCR Therapeutics, Inc.INDUSTRY | 1 | Apr 19, 2021 | clinicaltrials |
| NCT02104427 | PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | completed | Phase 2 | 12 | GPCR Therapeutics, Inc.INDUSTRY | 1 | Apr 19, 2021 | clinicaltrials |
| NCT01045460 | Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma(aMILs) | completed | Phase 2 | 36 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT04439214 | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2021 | clinicaltrials |
| NCT00773838 | Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) | completed | Phase 2 | 143 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 1, 2021 | clinicaltrials |
| NCT03262389 | Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma | completed | Phase 2 | 10 | Michael C Roarke, MDOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT01402284 | Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02078102 | A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma | completed | Phase 2 | 38 | Sherif S. FaragOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 10, 2022source: clinicaltrials